{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:24:08Z","timestamp":1794108248729,"version":"4.8.0"},"reference-count":126,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:00:00Z","timestamp":1652140800000},"content-version":"vor","delay-in-days":129,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ghadvances.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastro Hep Advances"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.gastha.2022.05.006","type":"journal-article","created":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T11:42:30Z","timestamp":1652528550000},"page":"882-893","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Silymarin for Treating Toxic Liver Disease: International Consensus Recommendations"],"prefix":"10.1016","volume":"1","author":[{"given":"Anton","family":"Gillessen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Angelico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lungen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Isabel","family":"Lucena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingchun","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul J.","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-min","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuemin","family":"Nan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastha.2022.05.006_bib1","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"James","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.gastha.2022.05.006_bib2","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.aohep.2019.09.007","article-title":"Calling a stage-based treatment model for chronic liver diseases in China mainland","volume":"19","author":"Liu","year":"2020","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.gastha.2022.05.006_bib3","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/hep.31173","article-title":"Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD","volume":"72","author":"Paik","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2022.05.006_bib4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","article-title":"Burden of liver diseases in the world","volume":"70","author":"Asrani","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gastha.2022.05.006_bib5","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/toxsci\/65.2.166","article-title":"Mechanisms of hepatotoxicity","volume":"65","author":"Jaeschke","year":"2002","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.gastha.2022.05.006_bib6","doi-asserted-by":"crossref","first-page":"53","DOI":"10.15171\/ijoem.2020.1771","article-title":"Polymorphism of glutathione S-transferase genes and the risk of toxic liver damage in petrochemical workers","volume":"11","author":"Valeeva","year":"2020","journal-title":"Int J Occup Environ Med"},{"key":"10.1016\/j.gastha.2022.05.006_bib7","first-page":"64","article-title":"From nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease: is it time for a change of terminology?","volume":"6","author":"Targher","year":"2020","journal-title":"Hepatoma Res"},{"key":"10.1016\/j.gastha.2022.05.006_bib8","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1177\/0192623312468517","article-title":"Toxicant-associated steatohepatitis","volume":"41","author":"Wahlang","year":"2013","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.gastha.2022.05.006_bib9","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s40572-019-00231-x","article-title":"Understanding environmental contaminants' direct effects on non-alcoholic fatty liver disease progression","volume":"6","author":"Armstrong","year":"2019","journal-title":"Curr Environ Health Rep"},{"key":"10.1016\/j.gastha.2022.05.006_bib22","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.3748\/wjg.v24.i30.3361","article-title":"Current guidelines for the management of non-alcoholic fatty liver disease: a systematic review with comparative analysis","volume":"24","author":"Leoni","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gastha.2022.05.006_bib23","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.3748\/wjg.v24.i13.1373","article-title":"Dissecting the molecular pathophysiology of drug-induced liver injury","volume":"24","author":"Ye","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gastha.2022.05.006_bib24","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S2468-1253(19)30349-8","article-title":"The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"5","author":"Sepanlou","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2022.05.006_bib25","doi-asserted-by":"crossref","first-page":"8082","DOI":"10.3748\/wjg.v20.i25.8082","article-title":"Oxidative stress as a crucial factor in liver diseases","volume":"20","author":"Cichoz-Lach","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gastha.2022.05.006_bib26","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3390\/antiox10030390","article-title":"Oxidative stress in drug-induced liver injury (DILI): from mechanisms to biomarkers for use in clinical practice","volume":"10","author":"Villanueva-Paz","year":"2021","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.gastha.2022.05.006_bib27","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/MAJ.0b013e31821d9905","article-title":"Oxidative stress in chronic liver disease: relationship between peripheral and hepatic measurements","volume":"342","author":"Vuppalanchi","year":"2011","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.gastha.2022.05.006_bib28","doi-asserted-by":"crossref","first-page":"26087","DOI":"10.3390\/ijms161125942","article-title":"The role of oxidative stress and antioxidants in liver diseases","volume":"16","author":"Li","year":"2015","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.gastha.2022.05.006_bib29","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.3390\/nu12092627","article-title":"Oxidative stress in chronic liver disease and portal hypertension: potential of DHA as nutraceutical","volume":"12","author":"Boyer-Diaz","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.gastha.2022.05.006_bib30","series-title":"Drug-induced liver injury (DILI): Current status and future directions for drug development and the post-market setting. A consensus by a CIOMS Working Group. Geneva, Switzerland: Council for International Organizations of Medical Sciences (CIOMS),","year":"2020"},{"key":"10.1016\/j.gastha.2022.05.006_bib20","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1136\/gutjnl-2019-319720","article-title":"Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting","volume":"69","author":"Avila","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.gastha.2022.05.006_bib31","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.4254\/wjh.v7.i10.1325","article-title":"Oxidative stress: new insights on the association of non-alcoholic fatty liver disease and atherosclerosis","volume":"7","author":"Polimeni","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.gastha.2022.05.006_bib32","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3390\/gastroent12020014","article-title":"Expert opinion on the management of non-alcoholic fatty liver disease (NAFLD) in the Middle East with a focus on the use of silymarin","volume":"12","author":"Hashem","year":"2021","journal-title":"Gastroenterol Insights"},{"key":"10.1016\/j.gastha.2022.05.006_bib33","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s12325-020-01251-y","article-title":"Silymarin as supportive treatment in liver diseases: a narrative review","volume":"37","author":"Gillessen","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.gastha.2022.05.006_bib37","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; Clinical Practice Guideline Panel: Chair; Panel Members. EASL clinical practice guidelines: drug-induced liver injury. J Hepatol 2019;70:1222\u20131261.","DOI":"10.1016\/j.jhep.2019.02.014"},{"key":"10.1016\/j.gastha.2022.05.006_bib41","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s12072-017-9793-2","article-title":"CSH guidelines for the diagnosis and treatment of drug-induced liver injury","volume":"11","author":"Yu","year":"2017","journal-title":"Hepatol Int"},{"key":"10.1016\/j.gastha.2022.05.006_bib10","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1053\/j.gastro.2019.02.002","article-title":"Incidence and etiology of drug-induced liver injury in mainland China","volume":"156","author":"Shen","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2022.05.006_bib39","doi-asserted-by":"crossref","first-page":"8894498","DOI":"10.1155\/2021\/8894498","article-title":"Epidemiology of drug- and herb-induced liver injury assessed for causality using the updated RUCAM in two hospitals from China","volume":"2021","author":"Chen","year":"2021","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.gastha.2022.05.006_bib40","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1478-3231.2007.01461.x","article-title":"Drug-induced liver injury at an Asian center: a prospective study","volume":"27","author":"Wai","year":"2007","journal-title":"Liver Int"},{"key":"10.1016\/j.gastha.2022.05.006_bib42","article-title":"Drug-induced liver injury: clinical and etiologic features at a large tertiary teaching hospital in China","volume":"26","author":"Liu","year":"2020","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.gastha.2022.05.006_bib43","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/6987295","article-title":"Isoniazid and rifampicin produce hepatic fibrosis through an oxidative stress-dependent mechanism","volume":"2020","author":"Biswas","year":"2020","journal-title":"Int J Hepatol"},{"key":"10.1016\/j.gastha.2022.05.006_bib38","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1055\/s-0034-1375955","article-title":"Clinical features, diagnosis, and natural history of drug-induced liver injury","volume":"34","author":"Hayashi","year":"2014","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.gastha.2022.05.006_bib122","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.metabol.2015.11.008","article-title":"Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"65","author":"Brown","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.gastha.2022.05.006_bib11","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gastha.2022.05.006_bib12","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic fatty liver disease 2020: the state of the disease","volume":"158","author":"Cotter","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2022.05.006_bib44","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the\u00a0Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2022.05.006_bib13","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S2468-1253(19)30342-5","article-title":"Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission","volume":"5","author":"Sarin","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2022.05.006_bib14","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030","volume":"69","author":"Estes","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gastha.2022.05.006_bib15","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/hep.25889","article-title":"Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients","volume":"56","author":"Bedossa","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2022.05.006_bib16","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/hep.27173","article-title":"Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease","volume":"60","author":"Bedossa","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2022.05.006_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-036663","article-title":"Prevalence trends in non-alcoholic fatty liver disease at the global, regional and national levels, 1990-2017: a population-based observational study","volume":"10","author":"Ge","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.gastha.2022.05.006_bib18","doi-asserted-by":"crossref","first-page":"e573","DOI":"10.1016\/j.cgh.2021.02.030","article-title":"Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in overweight or obese adults","volume":"20","author":"Liu","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2022.05.006_bib123","first-page":"22","article-title":"Non-alcoholic fatty liver disease: clinic, diagnostics, treatment","volume":"2","author":"Lazebnik","year":"2017","journal-title":"Exp Clin Gastroenterol"},{"key":"10.1016\/j.gastha.2022.05.006_bib124","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A\u00a0new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gastha.2022.05.006_bib52","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3390\/nu11040872","article-title":"Oxidative stress and non-alcoholic fatty liver disease: effects of omega-3 fatty acid supplementation","volume":"11","author":"Yang","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.gastha.2022.05.006_bib81","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","article-title":"The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease","volume":"14","author":"Eslam","year":"2020","journal-title":"Hepatol Int"},{"key":"10.1016\/j.gastha.2022.05.006_bib19","first-page":"55","article-title":"The emerging alcoholic liver disease in China","volume":"9","author":"Gao","year":"2016","journal-title":"North Am J Med Sci"},{"key":"10.1016\/j.gastha.2022.05.006_bib60","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/hep.30866","article-title":"Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases","volume":"71","author":"Crabb","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2022.05.006_bib61","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41572-018-0014-7","article-title":"Alcoholic liver disease","volume":"4","author":"Seitz","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.gastha.2022.05.006_bib59","unstructured":"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL clinical practice guidelines: management of alcohol-related liver disease. J Hepatol 2018;69:154\u2013181."},{"key":"10.1016\/j.gastha.2022.05.006_bib21","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1016\/j.cgh.2019.01.026","article-title":"Alcohol-related liver disease is rarely detected at early stages compared with liver diseases of other etiologies worldwide","volume":"17","author":"Shah","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2022.05.006_bib64","doi-asserted-by":"crossref","first-page":"4850","DOI":"10.2174\/092986712803341520","article-title":"Role of oxidative stress and molecular changes in liver fibrosis: a review","volume":"19","author":"S\u00e1nchez-Valle","year":"2012","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.gastha.2022.05.006_bib125","doi-asserted-by":"crossref","first-page":"878","DOI":"10.14309\/ajg.0000000000001259","article-title":"ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury","volume":"116","author":"Chalasani","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastha.2022.05.006_bib126","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1111\/apt.12963","article-title":"Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease","volume":"40","author":"Fedchuk","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastha.2022.05.006_bib127","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2013.07.042","article-title":"Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease","volume":"60","author":"Cusi","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gastha.2022.05.006_bib128","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1007\/s10620-016-4079-4","article-title":"Fibrosis assessment in nonalcoholic fatty liver disease (NAFLD) in 2016","volume":"61","author":"Kaswala","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gastha.2022.05.006_bib129","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/hep.24452","article-title":"Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis","volume":"54","author":"Hernaez","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2022.05.006_bib57","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1136\/gutjnl-2015-309265","article-title":"Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study","volume":"65","author":"Kwok","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.gastha.2022.05.006_bib120","doi-asserted-by":"crossref","first-page":"7088","DOI":"10.3748\/wjg.v26.i45.7088","article-title":"Chinese guidelines on the management of liver cirrhosis (abbreviated version)","volume":"26","author":"Xu","year":"2020","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gastha.2022.05.006_bib34","first-page":"73","article-title":"Drug-induced liver injury","volume":"6","author":"David","year":"2010","journal-title":"US Gastroenterol Hepatol Rev"},{"key":"10.1016\/j.gastha.2022.05.006_bib35","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.tips.2013.01.009","article-title":"Regulation of drug-induced liver injury by signal transduction pathways: critical role of mitochondria","volume":"34","author":"Han","year":"2013","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.gastha.2022.05.006_bib36","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1007\/s00204-020-02885-1","article-title":"Drug induced liver injury: an update","volume":"94","author":"Garcia-Cortes","year":"2020","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.gastha.2022.05.006_bib46","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3350\/cmh.2013.19.3.210","article-title":"Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis","volume":"19","author":"Koo","year":"2013","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.gastha.2022.05.006_bib47","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1046\/j.1440-1746.2001.02445.x","article-title":"Lipid peroxidation in hepatic steatosis in humans is associated with hepatic fibrosis and occurs predominately in acinar zone 3","volume":"16","author":"Macdonald","year":"2001","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2022.05.006_bib48","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/S0168-8278(03)00376-3","article-title":"Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis","volume":"39","author":"George","year":"2003","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gastha.2022.05.006_bib49","doi-asserted-by":"crossref","first-page":"360438","DOI":"10.1155\/2014\/360438","article-title":"Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal","volume":"2014","author":"Ayala","year":"2014","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.gastha.2022.05.006_bib50","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nrgastro.2015.200","article-title":"Immunology in the liver--from homeostasis to disease","volume":"13","author":"Heymann","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2022.05.006_bib51","doi-asserted-by":"crossref","first-page":"729","DOI":"10.21037\/atm-20-4354","article-title":"Non-alcoholic fatty liver disease (NAFLD)\/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention","volume":"9","author":"Tacke","year":"2020","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.gastha.2022.05.006_bib53","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis","volume":"52","author":"Tilg","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2022.05.006_bib54","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3390\/nu9040387","article-title":"Nonalcoholic fatty liver disease and insulin resistance: new insights and potential new treatments","volume":"9","author":"Kitade","year":"2017","journal-title":"Nutrients"},{"key":"10.1016\/j.gastha.2022.05.006_bib55","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/CM9.0000000000001263","article-title":"MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy","volume":"134","author":"Xian","year":"2020","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.gastha.2022.05.006_bib56","series-title":"Bioactive food as dietary interventions for diabetes","first-page":"3","article-title":"Chapter 1 - role of oxidative stress in the pathogenesis of insulin resistance and type 2 diabetes","author":"Henriksen","year":"2019"},{"key":"10.1016\/j.gastha.2022.05.006_bib62","first-page":"105","article-title":"Oxidative stress and antioxidative status in patients with alcoholic liver disease","volume":"23","author":"Shinde","year":"2012","journal-title":"Biomed Res"},{"key":"10.1016\/j.gastha.2022.05.006_bib63","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/00365510701673383","article-title":"Evaluation of blood oxidative stress-related parameters in alcoholic liver disease and non-alcoholic fatty liver disease","volume":"68","author":"Das","year":"2008","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.gastha.2022.05.006_bib65","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2022.05.006_bib66","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S2468-1253(19)30451-0","article-title":"Liver transplantation in patients with alcohol-related liver disease: current status and future directions","volume":"5","author":"Mathurin","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2022.05.006_bib67","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jhep.2010.09.022","article-title":"Intracellular reactive oxygen species are required for directional migration of resident and bone marrow-derived hepatic pro-fibrogenic cells","volume":"54","author":"Novo","year":"2011","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gastha.2022.05.006_bib68","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/112_2018_10","article-title":"Targeting oxidative stress for the treatment of liver fibrosis","volume":"175","author":"Luangmonkong","year":"2018","journal-title":"Rev Physiol Biochem Pharmacol"},{"key":"10.1016\/j.gastha.2022.05.006_bib69","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.3390\/ijms18051018","article-title":"Drug-induced liver injury: cascade of events leading to cell death, apoptosis or necrosis","volume":"18","author":"Iorga","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.gastha.2022.05.006_bib70","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/MPG.0000000000000279","article-title":"A\u00a04-polymorphism risk score predicts steatohepatitis in children with nonalcoholic fatty liver disease","volume":"58","author":"Nobili","year":"2014","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.gastha.2022.05.006_bib71","doi-asserted-by":"crossref","first-page":"852","DOI":"10.7150\/ijbs.19370","article-title":"Emerging roles of SIRT1\u00a0in\u00a0fatty liver diseases","volume":"13","author":"Ding","year":"2017","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.gastha.2022.05.006_bib72","article-title":"Genetic activation of Nrf2 protects against fasting-induced oxidative stress in livers of mice","volume":"8","author":"Zhang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.gastha.2022.05.006_bib73","doi-asserted-by":"crossref","first-page":"5823271","DOI":"10.1155\/2016\/5823271","article-title":"Oxidative stress and liver morphology in experimental cyclosporine A-induced hepatotoxicity","volume":"2016","author":"Korolczuk","year":"2016","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.gastha.2022.05.006_bib74","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3892\/ijmm_00000412","article-title":"Alleviation of hepatic oxidative stress by Chinese herbal medicine Yin-Chen-Hao-Tang in obese mice with steatosis","volume":"25","author":"Lee","year":"2010","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.gastha.2022.05.006_bib75","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/hep.1840160225","article-title":"Increased 4-hydroxynonenal levels in experimental alcoholic liver disease: association of lipid peroxidation with liver fibrogenesis","volume":"16","author":"Kamimura","year":"1992","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2022.05.006_bib76","doi-asserted-by":"crossref","first-page":"539","DOI":"10.24272\/j.issn.2095-8137.2020.051","article-title":"Assessment of mitochondrial function in metabolic dysfunction-associated fatty liver disease using obese mouse models","volume":"41","author":"Zhao","year":"2020","journal-title":"Zool Res"},{"key":"10.1016\/j.gastha.2022.05.006_bib77","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.2147\/DDDT.S237107","article-title":"Alleviation of liver dysfunction, oxidative stress and inflammation underlies the protective effect of ferulic acid in methotrexate-induced hepatotoxicity","volume":"14","author":"Roghani","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.gastha.2022.05.006_bib78","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3390\/nu12010158","article-title":"Oxidative stress parameters in the liver of growing male rats receiving various alcoholic beverages","volume":"12","author":"Kolota","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.gastha.2022.05.006_bib79","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/2042018810379587","article-title":"Advances in the treatment of nonalcoholic fatty liver disease","volume":"1","author":"Mehta","year":"2010","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.gastha.2022.05.006_bib80","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.metabol.2016.05.003","article-title":"Non-alcoholic fatty liver disease and dyslipidemia: an update","volume":"65","author":"Katsiki","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.gastha.2022.05.006_bib82","first-page":"163","article-title":"Guideline of prevention and treatment for nonalcoholic fatty liver disease: a 2018 update","volume":"20","year":"2019","journal-title":"Mod Med Health"},{"key":"10.1016\/j.gastha.2022.05.006_bib83","first-page":"358","article-title":"Effect of a comprehensive yoga-based lifestyle modification program on lipid peroxidation","volume":"49","author":"Yadav","year":"2005","journal-title":"Indian J Physiol Pharmacol"},{"key":"10.1016\/j.gastha.2022.05.006_bib84","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.lfs.2009.02.026","article-title":"Oxidative stress and metabolic syndrome","volume":"84","author":"Roberts","year":"2009","journal-title":"Life Sci"},{"key":"10.1016\/j.gastha.2022.05.006_bib85","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.metabol.2008.02.016","article-title":"High-fat, energy-dense, fast-food-style breakfast results in an increase in oxidative stress in metabolic syndrome","volume":"57","author":"Devaraj","year":"2008","journal-title":"Metabolism"},{"key":"10.1016\/j.gastha.2022.05.006_bib86","doi-asserted-by":"crossref","first-page":"E500","DOI":"10.1152\/ajpendo.00116.2007","article-title":"Exercise and diet induced weight loss improves measures of oxidative stress and insulin sensitivity in adults with characteristics of the metabolic syndrome","volume":"293","author":"Rector","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.gastha.2022.05.006_bib87","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1152\/japplphysiol.01292.2005","article-title":"Effect of a short-term diet and exercise intervention on oxidative stress, inflammation, MMP-9, and monocyte chemotactic activity in men with metabolic syndrome factors","volume":"100","author":"Roberts","year":"2006","journal-title":"J\u00a0Appl Physiol (1985)"},{"key":"10.1016\/j.gastha.2022.05.006_bib88","first-page":"239","article-title":"Reassessing bioavailability of silymarin","volume":"16","author":"Javed","year":"2011","journal-title":"Altern Med Rev"},{"key":"10.1016\/j.gastha.2022.05.006_bib89","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1002\/ptr.3207","article-title":"Milk thistle in liver diseases: past, present, future","volume":"24","author":"Abenavoli","year":"2010","journal-title":"Phytother Res"},{"key":"10.1016\/j.gastha.2022.05.006_bib90","doi-asserted-by":"crossref","DOI":"10.3390\/molecules22111942","article-title":"Silybin, a major bioactive component of milk thistle (Silybum marianum L. Gaernt.)-chemistry, bioavailability, and metabolism","volume":"22","author":"Bijak","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.gastha.2022.05.006_bib91","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/hep.510230415","article-title":"Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin","volume":"23","author":"Dehmlow","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2022.05.006_bib92","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.fct.2012.02.025","article-title":"Identification of novel mechanisms of silymarin on the carbon tetrachloride-induced liver fibrosis in mice by nuclear factor-kappaB bioluminescent imaging-guided transcriptomic analysis","volume":"50","author":"Li","year":"2012","journal-title":"Food Chem Toxicol"},{"key":"10.1016\/j.gastha.2022.05.006_bib93","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3892\/ijmm.2012.1029","article-title":"Silymarin suppresses hepatic stellate cell activation in a dietary rat model of non-alcoholic steatohepatitis: analysis of isolated hepatic stellate cells","volume":"30","author":"Kim","year":"2012","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.gastha.2022.05.006_bib94","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1590\/1414-431X20122551","article-title":"Effect and the probable mechanisms of silibinin in regulating insulin resistance in the liver of rats with non-alcoholic fatty liver","volume":"46","author":"Yao","year":"2013","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.gastha.2022.05.006_bib95","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0168-8278(01)00148-9","article-title":"Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen \u03b11 (I) and TIMP-1","volume":"35","author":"Jia","year":"2001","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gastha.2022.05.006_bib96","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.phrs.2009.12.017","article-title":"Silymarin suppress CD4+ T cell activation and proliferation: effects on NF-kappaB activity and IL-2 production","volume":"61","author":"Gharagozloo","year":"2010","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.gastha.2022.05.006_bib97","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2165\/00044011-200222010-00007","article-title":"Pharmacology of silymarin","volume":"22","author":"Fraschini","year":"2002","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.gastha.2022.05.006_bib98","doi-asserted-by":"crossref","first-page":"5004","DOI":"10.3748\/wjg.v23.i27.5004","article-title":"Effect of silymarin on biochemical indicators in patients with liver disease: systematic review with meta-analysis","volume":"23","author":"de Avelar","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gastha.2022.05.006_bib99","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000113648","article-title":"An updated systematic review with meta-analysis for the clinical evidence of silymarin","volume":"15","author":"Saller","year":"2008","journal-title":"Forsch Komplementmed"},{"key":"10.1016\/j.gastha.2022.05.006_bib100","first-page":"5","article-title":"Experts consensus on silymarin preparation in liver diseases","volume":"8","year":"2016","journal-title":"Chin J Hepatol"},{"key":"10.1016\/j.gastha.2022.05.006_bib101","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s15006-014-3758-3","article-title":"[Effect of silymarin on liver health and quality of life. Results of a non-interventional study]","volume":"156 Suppl 4","author":"Gillessen","year":"2014","journal-title":"MMW Fortschr Med"},{"key":"10.1016\/j.gastha.2022.05.006_bib102","doi-asserted-by":"crossref","first-page":"3192351","DOI":"10.1155\/2019\/3192351","article-title":"Prophylactic therapy of silymarin (milk thistle) on antituberculosis drug-induced liver injury: a meta-analysis of randomized controlled trials","volume":"2019","author":"Tao","year":"2019","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2022.05.006_bib103","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1186\/s12906-015-0861-7","article-title":"A\u00a0double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury","volume":"15","author":"Luangchosiri","year":"2015","journal-title":"BMC Complement Altern Med"},{"key":"10.1016\/j.gastha.2022.05.006_bib104","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0168-8278(89)90083-4","article-title":"Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver","volume":"9","author":"Ferenci","year":"1989","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gastha.2022.05.006_bib105","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3109\/00365528209182242","article-title":"Effect of silymarin on chemical, functional, and morphological alterations of the liver: a double-blind controlled study","volume":"17","author":"Salmi","year":"1982","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gastha.2022.05.006_bib106","doi-asserted-by":"crossref","DOI":"10.5812\/hepatmon.6099","article-title":"Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic fatty liver disease: a randomized controlled pilot study","volume":"12","author":"Hajiaghamohammadi","year":"2012","journal-title":"Hepat Mon"},{"key":"10.1016\/j.gastha.2022.05.006_bib107","first-page":"265","article-title":"A placebo-controlled trial of silymarin in patients with nonalcoholic fatty liver disease","volume":"9","author":"Hashemi","year":"2009","journal-title":"Hepat Mon"},{"key":"10.1016\/j.gastha.2022.05.006_bib108","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/MEG.0000000000001369","article-title":"Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial","volume":"31","author":"Anushiravani","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2022.05.006_bib109","article-title":"Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: a randomized, double-blind, placebo controlled trial","volume":"14","author":"Navarro","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.gastha.2022.05.006_bib110","first-page":"863","article-title":"[Effect of silimarin (Legalon) therapy on the antioxidant defense mechanism and lipid peroxidation in alcoholic liver disease (double blind protocol)]","volume":"131","author":"M\u00fczes","year":"1990","journal-title":"Orv Hetil"},{"key":"10.1016\/j.gastha.2022.05.006_bib111","first-page":"3118","article-title":"Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study","volume":"19","author":"Aller","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.gastha.2022.05.006_bib112","doi-asserted-by":"crossref","first-page":"8742075","DOI":"10.1155\/2019\/8742075","article-title":"Evaluation of the effect derived from silybin with vitamin D and vitamin E administration on clinical, metabolic, endothelial dysfunction, oxidative stress parameters, and serological worsening markers in nonalcoholic fatty liver disease patients","volume":"2019","author":"Federico","year":"2019","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.gastha.2022.05.006_bib113","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.cgh.2017.04.016","article-title":"A\u00a0randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis","volume":"15","author":"Wah Kheong","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2022.05.006_bib114","doi-asserted-by":"crossref","first-page":"2","DOI":"10.5414\/CPP40002","article-title":"Effects of silymarin MZ-80 on oxidative stress in patients with alcoholic cirrhosis. Results of a randomized, double-blind, placebo-controlled clinical study","volume":"40","author":"Lucena","year":"2002","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.gastha.2022.05.006_bib115","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0168-8278(97)80255-3","article-title":"Long-term (23 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients","volume":"26","author":"Velussi","year":"1997","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gastha.2022.05.006_bib116","first-page":"9","article-title":"Silymarin in treatment of non-alcoholic steatohepatitis: a randomized clinical trial","volume":"5","author":"Solhi","year":"2014","journal-title":"Caspian J Intern Med"},{"key":"10.1016\/j.gastha.2022.05.006_bib117","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1007\/s10620-006-9703-2","article-title":"The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: a pilot study","volume":"52","author":"Loguercio","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gastha.2022.05.006_bib118","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40268-015-0084-x","article-title":"Efficacy of lifestyle changes in subjects with non-alcoholic liver steatosis and metabolic syndrome may be improved with an antioxidant nutraceutical: a controlled clinical study","volume":"15","author":"Sorrentino","year":"2015","journal-title":"Drugs R D"},{"key":"10.1016\/j.gastha.2022.05.006_bib119","first-page":"188","article-title":"Guidelines of prevention and treatment for alcoholic liver disease (2018, China)","volume":"26","author":"Li","year":"2018","journal-title":"Chin J Hepatol"}],"container-title":["Gastro Hep Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S277257232200084X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S277257232200084X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T11:34:40Z","timestamp":1757417680000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S277257232200084X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":126,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022]]}},"alternative-id":["S277257232200084X"],"URL":"https:\/\/doi.org\/10.1016\/j.gastha.2022.05.006","relation":{},"ISSN":["2772-5723"],"issn-type":[{"value":"2772-5723","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Silymarin for Treating Toxic Liver Disease: International Consensus Recommendations","name":"articletitle","label":"Article Title"},{"value":"Gastro Hep Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastha.2022.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}]}}